<DOC>
	<DOCNO>NCT01464034</DOCNO>
	<brief_summary>This dose finding pilot study evaluate safety determine maximum tolerate dose combination carfilzomib pomalidomide dexamethasone ( CPD ) patient relapse refractory multiple myeloma follow phase II expansion MTD evaluate efficacy .</brief_summary>
	<brief_title>A Safety Efficacy Study Carfilzomib Pomalidomide With Dexamethasone Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>This dose finding pilot study evaluate safety determine maximum tolerate dose combination carfilzomib pomalidomide dexamethasone ( CPD ) patient relapse refractory multiple myeloma follow phase II expansion MTD evaluate efficacy . The study explore efficacy CPD include overall response , time progression , progression free survival , time next therapy .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Cytopathologically histologically confirm dx multiple myeloma Relapsed refractory recently receive therapy . All pt must receive prior lenalidomide therapy determine refractory , relapse , intolerant . Measurable disease , indicate one following : Serum Mprotein ≥ 0.5 g/dL Urine Bence Jones protein ≥ 200 mg/24 hr Elevated Free Light Chain per IMWG criterion , abnormal ratio Pts must ≥ 18 year age Life expectancy 3 month ECOG PS 02 Adequate hepatic function , bilirubin &lt; 2 time upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 time ULN Uric acid must within laboratory normal range CrCl ≥ 50 mL/min Additional Laboratory Requirements ANC ≥1.0 x 109/L Hgb ≥8 g/dL ( transfusion permit ) Platelet count ≥50.0 x 109/L Screening ANC independent granulocyteand granulocyte/macrophage colony stimulate factor ( GCSF GMCSF ) support least 1 week pegylated GCSF least 2 week Pts may receive RBC platelet transfusion , clinically indicate , accordance institutional guideline Screening platelet count independent platelet transfusion least 2 week . Written inform consent accordance federal , local , institutional guideline FCBP must agree ongoing pregnancy test FCBP must negative serum urine pregnancy test agree birth control . Male pt must agree never unprotected sexual contact female become pregnant must agree either completely abstain sexual contact female pregnant able become pregnant . The patient must agree inform physician unprotected sexual contact female become pregnant think reason sexual partner may pregnant . Male pts donate semen sperm take pomalidomide 28 day complete study . All pt must counsel minimum every 28 day pregnancy precaution risk fetal exposure . Pts must agree take entericcoated aspirin 81 mg orally daily , history prior thrombotic disease , must fully anticoagulated warfarin ( INR 23 ) treat fulldose , low molecular weight heparin , treat deep venous thrombosis ( DVT ) /pulmonary embolism ( PE ) investigator 's discretion Pts know sensitivity immunomodulatory drug ( IMiDs ) Use experimental drug therapy within 21 day prior first dose Exposure prior chemotherapy , steroid use , myeloma treatment within 14 day prior first dose . Pts currently long term steroid require washout period . addition , steroid use spinal cord compression permit require washout period . Radiation therapy within 14 day prior first dose Known allergy carfilzomib Captisol POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) Current diagnosis plasma cell leukemia Waldenström 's macroglobulinemia Major surgery within 21 day prior first dose Pregnant lactating female Congestive heart failure ( NYHA class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention myocardial infarction previous six month prior first dose . Uncontrolled hypertension Acute active infection require systemic antibiotic , antiviral , antifungal within 14 day prior first dose Pts receive active treatment intervention malignancy pt , Investigator 's discretion , may require active treatment intervention malignancy within 8 month start study treatment . Serious psychiatric medical condition could interfere treatment Significant neuropathy ( Grade 3 , Grade 4 , Grade 2 pain ) time first dose and/or within 14 day enrollment Contraindication require concomitant drug , include protonpump inhibitor ( e.g . lansoprazole ) , entericcoated aspirin history prior thrombotic disease , warfarin low molecular weight heparin Pts require program oral intravenous fluid hydration contraindicate , e.g . due preexist pulmonary , cardiac , renal impairment Pts primary systemic amyloidosis Pts receive prior treatment carfilzomib ( Phase II ) Pts receive prior treatment pomalidomide ( Phase II ) Pts receive prior treatment carfilzomib &amp; pomalidomide ( Phase I )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>